Vanguard Personalized Indexing Management LLC Acquires 1,540 Shares of Insulet Co. (NASDAQ:PODD)

Vanguard Personalized Indexing Management LLC raised its holdings in shares of Insulet Co. (NASDAQ:PODD) by 15.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 11,812 shares of the medical instruments supplier’s stock after acquiring an additional 1,540 shares during the period. Vanguard Personalized Indexing Management LLC’s holdings in Insulet were worth $2,368,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Orion Portfolio Solutions LLC grew its holdings in shares of Insulet by 276.6% in the fourth quarter. Orion Portfolio Solutions LLC now owns 10,221 shares of the medical instruments supplier’s stock worth $2,069,000 after purchasing an additional 7,507 shares during the last quarter. Diversified Trust Co grew its holdings in shares of Insulet by 90.9% in the second quarter. Diversified Trust Co now owns 9,130 shares of the medical instruments supplier’s stock worth $1,842,000 after purchasing an additional 4,348 shares during the last quarter. SG Americas Securities LLC grew its holdings in shares of Insulet by 349.3% in the first quarter. SG Americas Securities LLC now owns 29,575 shares of the medical instruments supplier’s stock worth $5,069,000 after purchasing an additional 22,993 shares during the last quarter. Allianz Asset Management GmbH grew its holdings in shares of Insulet by 85.1% in the fourth quarter. Allianz Asset Management GmbH now owns 108,109 shares of the medical instruments supplier’s stock worth $23,457,000 after purchasing an additional 49,715 shares during the last quarter. Finally, Duality Advisers LP grew its holdings in shares of Insulet by 89.4% in the first quarter. Duality Advisers LP now owns 19,131 shares of the medical instruments supplier’s stock worth $3,279,000 after purchasing an additional 9,029 shares during the last quarter.

Insulet Trading Down 0.5 %

Shares of PODD stock opened at $236.58 on Friday. The business’s fifty day moving average price is $202.19 and its 200 day moving average price is $187.67. The firm has a market capitalization of $16.59 billion, a PE ratio of 71.69, a P/E/G ratio of 4.38 and a beta of 1.21. The company has a debt-to-equity ratio of 1.36, a current ratio of 3.60 and a quick ratio of 2.71. Insulet Co. has a 1-year low of $125.82 and a 1-year high of $243.98.

Insulet (NASDAQ:PODD) last announced its earnings results on Thursday, August 8th. The medical instruments supplier reported $0.55 EPS for the quarter, missing analysts’ consensus estimates of $0.56 by ($0.01). The company had revenue of $488.50 million for the quarter, compared to analyst estimates of $488.00 million. Insulet had a net margin of 21.11% and a return on equity of 30.73%. Insulet’s quarterly revenue was up 23.2% compared to the same quarter last year. During the same quarter last year, the company posted $0.38 EPS. As a group, sell-side analysts forecast that Insulet Co. will post 3.04 EPS for the current fiscal year.

Analysts Set New Price Targets

PODD has been the subject of a number of research analyst reports. Piper Sandler raised their price target on Insulet from $230.00 to $285.00 and gave the stock an “overweight” rating in a research note on Tuesday. Canaccord Genuity Group reissued a “buy” rating and set a $234.00 price objective on shares of Insulet in a research report on Tuesday, July 23rd. Barclays lifted their price target on Insulet from $200.00 to $220.00 and gave the stock an “equal weight” rating in a research report on Monday, August 12th. BTIG Research lowered their price target on Insulet from $270.00 to $250.00 and set a “buy” rating for the company in a research report on Friday, August 9th. Finally, UBS Group lifted their price target on Insulet from $211.00 to $223.00 and gave the stock a “neutral” rating in a research report on Friday, August 9th. Four analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $229.21.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.